A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study

被引：42
作者：
Ghoshal U.C. [1 ]
Srivastava D. [1 ]
Misra A. [1 ]
机构：
[1] Department of Gastroenterology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow
来源：
Indian Journal of Gastroenterology | 2018年 / 37卷 / 5期
关键词：
Functional constipation; Functional gastrointestinal disorder; Gut microbiota; Irritable bowel syndrome; Lactulose hydrogen breath test; Rifaximin;
D O I：
10.1007/s12664-018-0901-6
中图分类号：
学科分类号：
摘要：
Objective: Gut microbe-derived methane may slow colon transit causing chronic constipation (CC). Effect of rifaximin on breath methane and slow-transit CC was evaluated. Method: Bristol stool form, frequency, colon transit time (CTT), and breath methane were evaluated in 23 patients with CC (10 patients with constipation-predominant irritable bowel syndrome [IBS-C], 13 functional constipation, Rome III) and m-ethane production compared with 68 non-constipating IBS. Methane-producing CC (basal ≥ 10 PPM and/or post-lactulose rise by > 10 PPM) was randomized (double-blind) to rifaximin (400-mg thrice/day, 2-weeks) or placebo. Stool forms, frequency, breath methane, and CTT were recorded afterward. Results: CC patients tended to be methane producer more often (13/23 [56.5%] vs. 25/68 [36.5%], p = 0.07) and had greater area under curve (AUC) for methane (2415 [435–23,580] vs. 1335 [0–6562.5], p = 0.02) than non-constipating IBS. Methane producers (8/13 [61.5%]) and 5/10 (50%) non-producers had abnormal CTT (marker retention: 36-h, 53 [0–60] vs. 19 [8–56], p = 0.06; 60-h, 16 [0–57] vs. 13 [3–56], p = 0.877). Six and 7/13 methane producers were randomized to rifaximin and placebo, respectively. Rifaximin reduced AUC for methane more (6697.5 [1777.5–23,580] vs. 2617.5 [562.5–19,867.5], p = 0.005) than placebo (3945 [2415–12,952.5] vs. 3720 [502.5–9210], p = 0.118) at 1 month. CTT normalized in 4/6 (66.7%) on rifaximin (36-h retention, 54 [44–57] vs. 36 [23–60], p = 0.05; 60-h, 45 [3–57] vs. 14 [11–51], p = 0.09) but none on placebo (p = 0.02) (36-h, 31 [0–60] vs. 25 [0–45], p = 0.078; 60-h, 6 [0–54] vs. 12 [0–28], p = 0.2). Weekly stool frequency (3 [1–9] and 7 [1–14], p = 0.05) and forms improved with rifaximin than placebo. Conclusion: Rifaximin improves CC by altering methane production and colon transit. Trial registration: Clinical Trial Registry, India: REF/2012/01/003216 [Figure not available: see fulltext.]. © 2018, Indian Society of Gastroenterology.
引用
收藏
页码：416 / 423
页数：7
相关论文
共 24 条
[1]  
Ghoshal U.C., Chronic constipation in Rome IV era: the Indian perspective, Indian J Gastroenterol, 36, pp. 163-173, (2017)
[2]  
Ghoshal U.C., Singh R., Frequency and risk factors of functional gastro-intestinal disorders in a rural Indian population, J Gastroenterol Hepatol, 32, pp. 378-387, (2017)
[3]  
Parthasarathy G., Chen J., Chen X., Et al., Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation, Gastroenterology, 150, pp. 367-79 e1, (2016)
[4]  
Triantafyllou K., Chang C., Pimentel M., Methanogens, methane and gastrointestinal motility, J Neurogastroenterol Motil, 20, pp. 31-40, (2014)
[5]  
Attaluri A., Jackson M., Valestin J., Rao S.S.C., Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS, Am J Gastroenterol, 105, pp. 1407-1411, (2010)
[6]  
Matsunami M., Tarui T., Mitani K., Nagasawa K., Fukushima O., Okubo K., Yoshida S., Takemura M., Kawabata A., Luminal hydrogen sulfide plays a pronociceptive role in mouse colon, Gut, 58, 6, pp. 751-761, (2008)
[7]  
Kunkel D., Basseri R.J., Makhani M.D., Chong K., Chang C., Pimentel M., Methane on breath testing is associated with constipation: a systematic review and meta-analysis, Dig Dis Sci, 56, pp. 1612-1618, (2011)
[8]  
Ghoshal U.C., Srivastava D., Verma A., Misra A., Slow transit constipation associated with excess methane production and its improvement following rifaximin therapy: a case report, J Neurogastroenterol Motil, 17, pp. 185-188, (2011)
[9]  
Pimentel M., Chang C., Chua K.S., Mirocha J., DiBaise J., Rao S., Amichai M., Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome, Digestive Diseases and Sciences, 59, 6, pp. 1278-1285, (2014)
[10]  
Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006)
123